Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205244
Title: | Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol |
Author: | Colet, Josep Comín Mainar, Antoni Sicras Salazar-mendiguchía, Joel Del Campo Alonso, María Isabel Echeto, Ainara Larena, David Vilanova Sánchez, Olga Delgado |
Keywords: | Medicaments cardiovasculars Anàlisi cost-benefici Cardiovascular agents Cost effectiveness |
Issue Date: | 25-Jul-2023 |
Publisher: | Becaris Publishing Limited |
Abstract: | Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. Results: 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of euro274/patient, from the perspective of society. Conclusion: Our results suggested that apixaban is a cost-effective alternative for patients with NVAF. |
Note: | Reproducció del document publicat a: https://doi.org/10.57264/cer-2023-0007 |
It is part of: | Journal of Comparative Effectiveness Research, 2023, vol. 12, num. 8 |
URI: | http://hdl.handle.net/2445/205244 |
Related resource: | https://doi.org/10.57264/cer-2023-0007 |
ISSN: | 2042-6313 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cer-2023-0007.pdf | 1.43 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License